Abeona Therapeutics Inc (ABEO)

NASDAQ
1.2100
0.0000(0.00%)
After Hours
1.2100
0.0000(0.00%)
- Real-time Data
  • Volume:
    300,937
  • Bid/Ask:
    1.1900/1.2300
  • Day's Range:
    1.1800 - 1.2300
  • Type:Equity
  • Market:United States
  • ISIN:US00289Y1073
  • CUSIP:00000289Y107

ABEO Overview

Prev. Close
1.21
Day's Range
1.18-1.23
Revenue
10M
Open
1.23
52 wk Range
0.9895-3.755
EPS
-0.58
Volume
300,937
Market Cap
122.48M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,032,666
P/E Ratio
-
Beta
1.49
1-Year Change
-41.83%
Shares Outstanding
101,227,014
Next Earnings Date
Nov 16, 2021
What is your sentiment on Abeona Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Abeona Therapeutics Inc News

Abeona Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralSellStrong SellStrong Sell
Technical IndicatorsBuyStrong BuyBuyStrong SellStrong Sell
SummaryNeutralBuyNeutralStrong SellStrong Sell

Abeona Therapeutics Inc Company Profile

Abeona Therapeutics Inc Company Profile

Employees
76

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Read More
  • the movement is not encouraging
    0
    • A silly report made me buy this.
      1
      • To the moon
        3
        • Trash stock - trash ceo!
          3
          • I have been waiting 4 months for the stock to return to a buying price ********of a stock
            0
            • Me too, i bought in october at 1,54$ only a trash
              0
          • I hate this stock!!!!
            3
            • it is falling. ******it. Can we see 3$ above?
              2
              • Abeo now go up. I'm waiting for 2.45. friends, does anyone have information about shares?
                0
                • why does this feeling go down? Does anyone have information? Can it be taken from these levels?
                  0
                  • going to 1.89
                    5
                    • ABEO going down i hope not much  i sold 2.31
                      2
                      • https://www.tipranks.com/news/article/billionaire-ken-griffin-pulls-the-trigger-on-these-2-penny-stocks/
                        0
                        • reddit
                          0
                          • See in 8$ soon ❤️
                            0
                            • Any news about it
                              0
                              • told you good time coming soon 😃
                                0
                                • Can somebody share the information about the conference!!!
                                  0
                                  • how can we watch conference
                                    0
                                    • Momentum here is building
                                      0
                                      • let us see this today.
                                        0
                                        • This stock will have good day soon.
                                          1
                                          • Puhhhh patience .....
                                            0
                                        • Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20
                                          0
                                          • Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
                                            1
                                            • There might be some concerns regarding their listing on Nasdaq. They've been non-compliant since November 5th. It's pretty easy to solve the problem. Some people probably waited for some info about this issue on the webinar on Feb 16. Unlikely, the company's director said nothing about this.
                                              0
                                              • Lmao you just copied MY comment from Yahoo Finance 😂😂😂
                                                0
                                              • LOL
                                                0
                                            • Hopefully is the most frequently used word in this thread lmao))
                                              0
                                              • Right ive learned with abeona - "Hope" is never a good strategy...
                                                0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.